WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

COMPREHENSIVE REVIEW ON VACCINE REGULATION IN INDIA

Ms. Srushti Ramdas Shinde[1] , Ms. Prajkta Balakshe[2] , Dr. V. K .Redasani[3] ,Ms. Sanika Dhananjay Sapate [4]

Yashoda Shikshan Prasark Mandal, Yashoda Technical Campus, Faculty of Pharmacy (B Pharmacy), Wadhe Satara – 415001
srushtishinde1443@gmail.com

1.ABSTRACT:

Vaccine regulation is essential to maintaining public safety and health. An international viewpoint on vaccine regulation was examined, with particular attention to India's approach. The development of vaccination regulation over time reveals important occasions that influenced regulatory frameworks. Along with the crucial role played by the WHO through its prequalification program, the involvement of National Regulatory Authorities (NRAs) in guaranteeing the safety, effectiveness, and quality of vaccines is also covered. The pre-licensure review and post-licensure surveillance phases of the regulatory review procedure are described. With an emphasis on the primary regulatory agency is the Central Drugs Standard Control Organization (CDSCO). the Indian viewpoint is investigated. There is discussion of the stringent vaccine approval procedure, emergency use authorisation, vaccination administration and distribution, and post-marketing surveillance. Highlighted are the Indian government's involvement in global partnerships and focus on domestic vaccine research. This thorough analysis emphasises the significance of vaccine regulation as well as the measures the Indian government has taken to guarantee the security, effectiveness, and accessibility of vaccinations.

Keywords: Vaccine, Registration process, Central Drugs Standard Control Organisation, India, Safety, Vaccine Regulation, WHO etc.

2.INTRODUCTION:

A vital public health measure, vaccination shields millions of people each year from illnesses, disabilities, and death. In India, vaccinations are regulated by the Department of Biotechnology (DBT) in collaboration with the central Drugs Standard Control Organization (CDSCO) the Review Committee on Genetic Manipulation (RCGM), the DBT is in charge of the creation and prior to clinical testing of biologic recombinants, while the national regulatory agency that ensures vaccination quality, safety, and efficacy is CDSCO.[1]

Edward Jenner coined the term "vaccine" in 1796 after developing a vaccination against chickenpox using cowpox. Vaccines nowadays are biological agents that use weakened or dead forms, toxins, or surface proteins to create immunity against particular disease-causing bacteria. Immunisation can be preventive or therapeutic, and incorporating it into national immunisation programs necessitates a thorough regulatory evaluation. [4]

A number of organisations are involved in the production and promotion of vaccines in India. Regulatory agencies have set up frameworks to control vaccine development, assessment, and approval for the purpose of guarantee the effectiveness and security of these products. [8]

With an emphasis on maintaining public health safety and advancing vaccine development, this article attempts to investigate the regulatory environment of vaccine regulation in India, looking at the functions of CDSCO and DBT as well as the prerequisites for vaccine approval.

3.ROLE AND RESPONSIBILITIES OF CDSCO:

1. The Central Drugs Standard Control Organization, or CDSCO, is governed by the Drugs and Cosmetics Act.is entrusted with responsibilities such as approving new drugs, authorizing clinical trials, setting national drug quality standards, regulating imported medicines, and working with State Drug Control Authorities to ensure consistent application of regulations across India.
2. In collaboration with state agencies, CDSCO grants licenses for key drug categories like vaccines, blood products, large volume parenteral (LVPs), and sera.
3. The agency also issues test licenses, personal use licenses, and No Objection Certificates (NOCs) for exports.
4. It plays a central role in enforcing the and proposes amendments to the law when necessary.
5. CDSCO organizes meetings of key advisory bodies such as the Drugs Consultative Committee (DCC) and the Drugs Technical Advisory Board (DTAB) to address regulatory and technical issues.
6. It defines the regulatory guidelines ensuring the quality, safety, and effectiveness of pharmaceuticals and medical devices in India.
7. The agency is responsible for publishing and regularly updating the Indian Pharmacopoeia, which outlines standards for drugs and medical devices.
8. CDSCO authorizes certified institutions to perform testing and compliance checks to uphold quality standards for drugs and medical devices.

9. In addition to regulation, CDSCO monitors adverse drug reactions, distributes technical information, and offers training programs for regulatory and quality personnel.
10. It collaborates with international organizations like the WHO to support global harmonization of regulations and ensure adherence to Good Manufacturing Practices (GMP).
11. CDSCO operates through zonal offices across the country that manage inspections before and after licenses are issued, oversee market surveillance, and carry out product recalls when necessary.[6]

4.CONCEPTUALIZING THE VACCINE:



Fig 1. diagram Outlining the vaccine's conceptualization[17]

STAGE	AGENCY	APPLICATION	APPROVAL
License for test, manufacture, analysis	State authority/ CDSCO	Form 30	Form 29
Preclinical permission	RCGM	Form C3	Form C4
Submission of preclinical report	RCGM	Form C5	Form C6
Clinical trials	CDSCO	Form 44	Permission letter
Manufacturing and marketing	CDSCO	Form 44	Form 46
Manufacturing license	State authority	Form 27D	Form 28D
Registration and import	CDSCO	Form 8	Form 10

Table 1. Showing stages, agency, application and approval of vaccine.[4]

5.VACCINE APPROVAL IN INDIA:

Approvals of New Drugs: CDSCO is in charge of approving new medications, including vaccines, and guaranteeing their quality, safety, and effectiveness.
Clinical Trial Regulation: CDSCO oversees clinical trials to make sure they follow ethical guidelines and Good Clinical Practice (GCP).
Imported Drug Quality Monitoring: To guarantee the safety and effectiveness of imported medications, including vaccines, CDSCO keeps an eye on their quality.
Coordination with State Drug Organisations: To guarantee consistent implementation of the CDSCO collaborates with the state under the Drugs and Cosmetics Act drug organisations.

Making Certain Safety and Effectiveness

Before being made available to the general public, national regulatory organisations like CDSCO make sure that vaccinations and related goods fulfil strict quality, safety, and efficacy requirements.

This comprises:

Thorough Regulation: To guarantee thorough regulation and oversight during the vaccine approval process, regulatory authorities examine and improve procedures.

Coordination and Collaboration: To guarantee that vaccinations are high-quality, safe, and effective, regulatory agencies work together and coordinate with one another.

In order to safeguard India's public health, CDSCO is essential in guaranteeing the efficacy, safety, and quality of vaccines. [1, 3]



Fig 2. Regulatory Authorities for Registration of Vaccines

Development process of vaccine:

The development of vaccines is a highly regulated and complex process that ensures the safety, effectiveness, and quality of every product prior to it reaches the public. Central to this process are clinical trials, which are essential for assessing how a vaccine performs in real-world conditions. In India, a vaccine must first undergo pre-clinical evaluations, followed by three distinct phases of clinical trials before it is approved for public use. These trials are designed based on a well-structured plan that considers socioeconomic factors, population vulnerability, disease prevalence, safety profiles, and environmental risks. Other important elements such as the appropriate dosage, method of administration, and strategies for public awareness are also evaluated before large-scale immunization can begin.

In India, clinical trials for vaccines must comply with the 1940 Drugs and Cosmetics Act's Schedule Y and its 1945 Rules. This legal framework sets detailed requirements for the importation and trial conduct of new drugs, including vaccines. Sponsors conducting biologics trials must submit an application for a clinical trial (Form 44). and a report to the CMC (Chemistry, Manufacturing, and Controls) Drug Controller General of India (DCGI). All trials must follow Guidelines from the International Conference on Harmonization-Good Clinical Practice (ICH-GCP), and data collection, monitoring, and reporting are performed under stringent Quality Assurance standards. Regular updates must be submitted to regulatory authorities, and any Within 14 days, significant adverse events (SAEs) must be recorded. If a trial is discontinued early, a comprehensive final report is required within three months.

Traditionally, the entire process of vaccine development—from research to market—spanned 10 to 15 years due to the extensive testing and approval steps involved. However, recent technological advancements, regulatory flexibility, and collaborative efforts among global experts have significantly shortened this timeline. The development of COVID-19 vaccines is a prime example, with safe and effective vaccines reaching the market in just 12 to 18 months. Despite the speed, the safety record of vaccines has remained strong, with only rare and infrequent adverse effects reported over the years, supporting public confidence in widespread immunization programs. [1,4]



Fig 3. Different phases of drug development

Explotary Stage of Vaccine Development:

The exploratory stage of vaccine development focuses on identifying a suitable antigen to target a specific disease. It involves basic laboratory research over 2–4 years, studying weakened pathogens, virus-like particles, or derived substances. This phase is slow and complex, requiring multiple approvals and significant funding. Despite the challenges, it lays the foundation for selecting a promising antigen for further development. [2].

Pre-Clinical Stage:

The preclinical stage of vaccine development assesses safety, immune response, and efficacy through lab techniques and animal testing, typically lasting 1–2 years. Mice and monkeys are commonly used to evaluate cellular responses, while challenge studies test protection against the actual pathogen. This phase helps determine the safest dose, ideal administration route, and possible failures. Key outcomes guide whether the vaccine proceeds to human trials. After completion, developers submit lab data, production details, and study plans for review. Approval from an institutional board and submission of Forms 44, 45, and 46 are required to move to clinical trials [4]

IND Application:

In India, a sponsor (typically a pharmaceutical company) submits an IND application to the Central Drugs Standard Control Organisation (CDSCO) for approval. In The following items must be included in the IND application:

information about animal research and toxicity.

Creating study plans, or clinical procedures, for the research that will be conducted.

Data from any previous human research.

Details regarding the investigator

Any further information:

Approval Procedure:

1.Institutional Ethics Committee (IEC) approval.

2.CDSCO review within 30 days

3.Approval for clinical trials (Phases I-III) _Indian Regulatory Framework: _CDSCO oversees IND applications under: Drugs and Cosmetics Act, 19402.

Clinical trials phases: Study of vaccines on human.

Phase 1 trials:

Phase 1 trials: The first stage of human testing, phase I clinical trials evaluate the safety, tolerability, and immune response of vaccines while determining the maximum safe dosage. These non-blinded (open label) studies, which are characterised by small group sizes (less than 100 participants), track systemic and local side effects and assess immunological responses over a period of several months. Safety, tolerability, immunogenicity (immune response), and dosage optimisation are the main goals. At least 70% of studies must be successful in order to move on to Phase II trials. Phase I trials are primarily concerned with vaccination safety, dosage calculation, and preliminary efficacy evaluation.[1]

Phase 2 trials:

Phase II vaccination trials aim to increase the safety, immunogenicity, and efficacy of vaccines. In order to evaluate the vaccine's safety, efficacy, and immunogenicity while tracking side effects, this phase uses a comparative trial design, comparing the vaccination against a placebo.

Phase II studies, which usually have several hundred people, produce important results such as an improved vaccine formulation, a vaccination schedule, the identification of possible adverse effects, and the assessment of efficacy in various demographics. Larger-scale Phase III trials are made possible by the optimisation of the vaccine and its administration schedule based on these findings.[4]

Phase 3 trials:

Phase III vaccine studies are essential for verifying a vaccine's effectiveness, safety, and ideal dosage in a sizable population of 1,000–3,000 participants over a one–four-year period. The outcomes of the vaccinated and unvaccinated (placebo) groups are compared in these double-blind, randomized trials. Assessing immunogenicity, short-term adverse effects, tolerance, and age-related efficacy are the main objectives. Although a minimum of 33% efficacy is usually required for these trials to be considered successful, between 70 and 75 percent of vaccine candidates fail at this point because of issues with complex design, guaranteeing lot-to-lot manufacturing uniformity, and the effects of co-administered vaccines.

Several hundred members of the target demographic as well as vulnerable groups are included in the study population. The well-controlled trials seek to establish a strong safety profile and identify the best, safest, and most effective dosage. Successful trial results result in regulatory approval and open the door for broader public distribution. These trials are essential for thorough vaccination evaluation prior to public release since they must also detect differences in immune response across various formulations and age groups.

Organisation for Central Drug Standard Control (CDSCO) is in charge of approving vaccines in India; the Expert Committee and the India's Drug Controller General (DCGI) assess applications. Data from clinical trials, vaccine composition, quality control and stability data, and preclinical and clinical reports are among the comprehensive paperwork that developers are required to submit the 1940 Drugs and Cosmetics Act, Schedule Y, ICMR, and CDSCO guidelines are examples of regulatory systems. After receiving permission, producers move further with post-marketing surveillance, logistics, quality assurance, scale-up, and efforts to be included in the National Immunisation Program (NIP), which necessitates Ministry of Health and Family Welfare approval and NTAGI recommendations. Regulatory review takes 6–12 months, manufacture and distribution take 3–6 months, and continuous safety monitoring is part of the process. Inspection and application fees are between ₹20,000 and ₹50,000 and ₹50,000 and ₹200,000, respectively. [1,4]

Phase 4 trials :

Phase IV research After being licensed and approved, a vaccine often proceeds into phase IV trials, which entail ongoing research. The vaccine's manufacturer continues to test it at this point to ensure that it is safe and effective for sale. The term " Phase IV trials that assess optimal use, safety, and efficacy are frequently referred to as "postmarketing surveillance studies." Programs for pharmacovigilance regularly evaluate the vaccine's side effects, and records are maintained during this ongoing study..[1]



fig 4. Pathway for approval of clinical trials

The function of India's ethics committee:

In India, an ethics committee is a multidisciplinary team with at least seven members who have received training in accordance with the rules set forth by the Central Licensing Authority. Members come from a variety of backgrounds, including non-medical ones. The committee is in charge of examining clinical trial proposals to make sure they adhere to ethical guidelines both domestically and abroad. By examining trial procedures, informed consent

forms, investigator qualifications, participant confidentiality, and serious adverse events (SAEs), it seeks to protect trial participants' welfare, safety, and rights. To guarantee ethical compliance, the committee may ask for protocol modifications, put a stop to research, or monitor trials that have been finished. Before managing any clinical trials, the ethical committee needs to be registered with the Central Licensing Authority. Rule 7 and Rule 8 of India's regulatory framework govern this. After submitting an application using Clinical Trial Form-04, the committee is granted registration via Form-06, which is good for two years. Clinical trial approval is valid for three years, and three months prior to that time, re-registration is necessary. The central authority gives a written explanation for rejection if it is not happy with the application. Additionally, the committee oversees reports of any significant adverse events during trials and makes sure that trials adhere to Good Clinical Practice (GCP) recommendations.

The ethics committee can halt the trial or suspend it if participant safety is jeopardised. To verify GCP compliance, the Central Licensing Authority and state authorities may surprise trial sites with inspections. Any institutional non-compliance with the New Drugs and Clinical Trials Rules, 2019 could lead to warnings or disqualification from further trials. All things considered, the ethics committee is essential to the ecosystem of clinical trials in India for ethical supervision, participant protection, and research integrity. [1]

Approval Procedure :

Approval Process: The vaccine approval process is essential to safeguarding the public's health for several reasons. The main goal of vaccines is to prevent infectious diseases by improving the immune system's capacity to identify and combat specific germs.

When a vaccine is approved, it indicates that it has undergone rigorous tested and shown to be secure and efficient in preventing a certain disease. By guaranteeing the manufacturing, distribution, and use of safe and effective vaccines, this process also helps to build public confidence in the medical system by ensuring that vaccine producers adhere to strict standards and regulations.

To standardise the clearance process, vaccine-related documentation is submitted using the Five modules make up the Common Technical Document (CTD) format: administrative information, quality overview, quality information, non-clinical data, and clinical data. In accordance with the regulations, the manufacturer provides the CDSCO with hard copies and digital copies of these documents in both paper and electronic CTD format for potential future use.. [7]



Fig 5.Approval process of vaccine in India

6.PHARMACOVIGILANCE IN VACCINE REGULATION: ENSURING SAFETY AND EFFICACY:

Pharmacovigilance is essential for tracking vaccine safety, assessing side effects, and averting injury. Continuous monitoring is necessary since immunisations might cause negative reactions in certain people. Important facets of vaccine pharmacovigilance consist of:

1. Constant observation of safety information from many sources (clinical studies, patient reports, and medical records).

2. Frequent analysis to evaluate benefit-risk balance and spot safety trends.

3. Prompt identification, evaluation, and mitigation of negative consequences. [9]

The nation has a strong system in place to track adverse events that occur after vaccination (AEFI).
India's pharmacovigilance program is supervised by the Central Drugs Standard Control Organisation (CDSCO). The National Coordinating Centre (NCC) for Pharmacovigilance is located at the All-India Institute of Medical Sciences (AIIMS) in New Delhi.

India uses Vigo-flow software for ADR reporting as part of the WHO's International Drug Monitoring program.

Relevance to India:
Pharmacovigilance is essential to guaranteeing the safety and effectiveness of vaccines in India, given the country's growing vaccination landscape. As the need for affordable, convenient immunisations grows.

Pharmacovigilance aids in:

Monitoring adverse events;

Improving vaccination safety and acceptability.

Provide guidance for evidence-based vaccination policy. [10]

Adverse events after vaccination (AEFI) are tracked, possible hazards are identified, and prompt responses are facilitated. Promotes international immunisation programs;

improves patient safety and public trust; and guarantees data integrity, security, and openness. [8]

Pertinence to the Indian Regulatory Structure:
This data demonstrates the necessity of:

Sturdy monitoring mechanisms, underscoring the significance of pharmacovigilance in India's vaccination regulatory framework.

Effective reporting of adverse events; ongoing assessment of the safety and effectiveness of vaccines. [10]

Pharmaceutical companies in India have implemented post-marketing pharmacovigilance methods.
1. SIDDAR App: As a component of the AYUSH pharmacovigilance program, this mobile app allows users to report adverse drug reactions (ADRs) in Siddha medicine.
2The National Pharmacovigilance Coordination Centre (NPvCC), located in New Delhi at the All India Institute of Ayurveda, is in charge of pharmacovigilance for ASU and H drugs.

3. Sanofi Pasteur's Global Pharmacovigilance Database: Tracks side effects associated with the anti-rabies immunoglobulin FAVIRAB (F(ab')2 PERIG).

Key Features:
- Time consumption reduction and promotion of prudent prescription practices;
- Real-time ADR documentation and reporting
- Cooperation among medical staff, patients, and consumers;
- Evaluation of causality and investigation of reported adverse drug reactions;
- Worldwide database for monitoring adverse occurrences

Relevance:

The Indian pharmacovigilance regulations that guarantee the safety and effectiveness of traditional medicines (homoeopathy, Siddha, Ayurveda, and Unani)

enhancing public health and patient safety. [11]

Pharmacovigilance Programme in India :

On July 14, 2010, the all India Institute of Medical Sciences (AIIMS), located in New Delhi, was established as the National Coordination Centre for the Pharmacovigilance Programme of India (PvPI).

Its main objective is to safeguard public health by tracking and evaluating adverse drug reactions.

Key Objectives:

- Establish a national patient safety reporting system.
- Find and examine fresh indications from cases that have been reported.
- Examine the marketed drugs' benefit-risk ratio.
- Produce data on medication safety that is supported by evidence.
- Assist regulatory bodies in making decisions.
- Share safety information with interested parties.
- Become a premier national hub for pharmacovigilance initiatives.

The PvPI program was implemented in four phases between 2010 and 2015 and has three expert panels:

1. Quality Review Panel: Assesses Individual Case Safety Reports (ICSR) for completeness and accuracy.
2. Signal Review Panel: identifies and evaluates ICSR signals and suggests regulatory actions
3. Core Training Panel: Works on pharmacovigilance training initiatives with international organisations.

As of 2018, India had 250 Adverse Drug Reaction Monitoring Centres, with most located in Karnataka, Uttar Pradesh, and Maharashtra. The Indian Pharmacopoeia Commission has been the program's national coordinating organisation since 2011..[12]



Fig 6.Route of communication in India Pharmacovigilance Programme India.

7.REVOLUTIONZING VACCINE DEVELOPMENT WITH ARTIFICIAL INTELLEGENCE (AI) IN INDIA:

The application of artificial intelligence (Al) is causing a revolutionary change in the healthcare sector, especially in the area of vaccine development. Al's capacity to mimic human intellect and learn from intricate data has significant ramifications for the vaccine market in India. The creation of vaccines can be expedited, enhanced, and made more efficient by utilising Al technology.

Al in Vaccine Development: A Game-Changer
Large-scale data analysis, pattern recognition, and prediction capabilities of Al-powered systems allow for:
- Better development and design of vaccines.
- Better planning and execution of clinical trials.

• Better tracking of vaccine efficacy and safety.
• Tailored vaccination advice.
• Simplified regulatory clearances.

Important Al Technologies in Vaccine Development:
Natural Language Processing (NLP) for data extraction and literature analysis
Machine Learning (ML) for pattern identification and predictive modelling
Computer vision for diagnostics and image analysis
Deep Learning for intricate predictions and data analysis

Al Applications in Healthcare: Implications for Vaccine Regulation in India
• Diagnostic Support: AI systems are very good at deciphering medical images, such as X-rays, CT scans, and MRIs. They can sometimes do better than human radiologists, especially when it comes to identifying early signs of diseases like cancer.

• Predictive analytics: AI systems are able to predict patient outcomes, such as the likelihood of contracting specific illnesses or having them recur. These revelations improve patient care and aid in the creation of individualised treatment plans.

• Enhanced Drug Development: AI greatly reduces the time and cost associated with creating new drugs by accelerating the drug discovery process by analysing intricate biological data to identify possible therapeutic candidates.

• Personalised Medicine: AI enables the creation of more accurate and efficient healthcare solutions by customising treatment regimens based on personal information such as genetic composition, lifestyle choices, and medical history.

• Enhanced Operational Efficiency: AI improves hospital operations, including patient flow, resource management, and appointment scheduling, which lowers costs and increases efficiency..[14]

8.CHALLENGS AND FUTURE PROSPECTS OF VACCINE REGULATION IN INDIA :

1. Complex Regulatory Process: India's vaccine regulatory process is intricate, involving multiple bodies like CDSCO, NTAGI, and MoHFW. This can lead to delays and confusion, especially during emergencies like pandemics.
2. Quality Control and Manufacturing Standards: Ensuring uniform quality across vaccine production facilities is a challenge. Maintaining consistent GMP standards across a vast and decentralized network of manufacturers can be difficult.
3. Compliance with International Standards: Meeting both domestic and international regulatory standards, such as WHO prequalification for exports, requires extensive testing and documentation. Disparities between Indian and international standards can hinder Indian vaccine manufacturers' access to global markets.
4. Intellectual Property and Licensing: Vaccine development involves intellectual property challenges, especially for emerging diseases like COVID-19. Limited access to certain patents and the need for licensing agreements can restrict production, delay rollout, and increase costs.
5. Supply Chain and Cold Storage Issues: The distribution of vaccines, especially those requiring ultra-low temperatures, faces logistical challenges in India. Regulatory measures must address transportation, storage, and delivery standards, particularly in rural areas with limited infrastructure.
6. Vaccine Hesitancy and Public Trust: Public perception and trust in vaccines are affected by misinformation, especially on social media. Regulatory bodies must work to address vaccine hesitancy through transparent approval processes and clear public communication strategies.
7. Limited Research and Development Resources: India's domestic R&D capabilities are still developing, and the government is working to increase funding. However, current limitations affect India's capacity for rapid vaccine innovation.

Future perspectives of vaccine regulation:

1.Complex Regulatory Process:

India’s vaccine regulatory process is intricate, involving multiple bodies like the Ministry of Health and Family Welfare (MoHFW), the National Technical Advisory Group on Immunisation (NTAGI), and the Central Drugs Standard Control Organisation (CDSCO). The imbrication in functions frequently leads to detainments and confusion, especially during extremities like afflictions

2. Quality Control and Manufacturing Standards:

Ensuring uniform quality across vaccine production facilities is challenging. While India has strong production capabilities, maintaining consistent Good Manufacturing Practices (GMP) standards across a vast and decentralized network of manufacturers can be difficult.

3.Compliance with International Standards:

Meeting both domestic and international regulatory standards, such as WHO prequalification for exports, requires extensive testing and documentation. the disparity between Indian and international standards can hinder Indian vaccine manufacturers’ access to global markets.

4.Intellectual Property and Licensing:

Vaccine development involves intellectual property challenges, especially for COVID-19 and other emerging diseases. Limited access to certain patents and the need for licensing agreements can restrict production, delay rollout, and increase costs.

5.Supply Chain and Cold Storage Issues:

The distribution of vaccines, especially those requiring ultra-low temperatures, faces logistical challenges in India. Regulatory measures must also address transportation, storage, and delivery standards, particularly in rural areas with limited infrastructure.

6.Vaccine Hesitancy and Public Trust:

Public perception and trust in vaccines are affected by misinformation, especially on social media. Regulatory bodies must work to address vaccine hesitancy through transparent approval processes and clear public communication strategies.

7.Limited Research and Development Resources:
Despite being a major vaccine producer, India's domestic R&D capabilities are still developing. The government is working to increase funding, but the current limitations affect India's capacity for rapid vaccine innovation.[1]

9.CONCLUSION

In conclusion, the Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) are the two main government agencies involved in the intricate and cooperative process of vaccine regulation in India. Together, they guarantee vaccination quality, safety, and effectiveness from early clinical studies to post-market monitoring. Another important player in this regulatory environment is the Indian Council of Medical Research (ICMR).
India's vaccine approval process is comprehensive, requiring adherence to Good Manufacturing Practices (GMP), clinical data submission, and specific labelling requirements. Pharmacovigilance initiatives, such as the Pharmacovigilance Programme of India (PvPI), are essential for tracking side effects after approval and guaranteeing the long-term safety of vaccines.
The use of AI in this area is emerging, providing new ways to enhance safety monitoring.
However, challenges remain, such as streamlining regulatory pathways, increasing transparency, and fostering indigenous vaccine development. Recent regulatory updates and additional funding signal a positive shift toward addressing these challenges. Looking forward, India aims to further strengthen its regulatory framework, support local vaccine innovation, and leverage advanced technologies to improve public health outcomes.

10.REFERENCE :

1.Rakshita Salalli, Jyoti Ram Dange, Sonia Dhiman, Teenu Sharma.Vaccines development in India: advances, regulation, and challengesClin Exp Vaccine Res 2023;12:193-208.
2 .M. Bhargavi Thanuja, Ramaiah Maddi21.Comparison of regulatory approval process for vaccines development and manufacturing in India & USA.UPI Journal of Pharmaceutical Medical,and Health Sciences 4 (4) 2021: 18 - 24 ISSN : 2581-4532.
3.Aanal Shah, Mr. Darshil Shah Dr. Dilip Maheshwari. A Comprehensive Study on Comparison of Registration Process of Vaccine in INDIA and USA.JOURNAL OF PHARMACEUTICAL SCIENCE AND BIOSCIENTIFIC RESEARCH (JPSBR)JPSBR: Volume 4, toe 2: 2014 (163-171) 155N NO.
2271-3681.
4.Vivek Kumar Bihania and Ashutosh Badola .Regulatory aspects for vaccines in India and US. International Journal of Drug Regulatory Affairs. 2020; 8(1): 44-50.
5.Vipin M Vashishtha. National Vaccine Policy of India January 2014DOI: 10.5005/jp/books/12311_59.
6.Central Drugs Standard Control Organisation (CDSCO) - https://cdsco.gov .in.
7.Dellepiane N, Pagliusi S; Registration Experts Working Group. Challenges for the registration of vaccines in emerging countries: differences in dossier requirements, application and evaluation processes. Vaccine 2018;36: 3389-96.
8.K. Sailaja, Bogireddy Indra Sena Reddy, BLOCKCHAIN AND PHARMACOVIGILANCE: SECURING VACCINE SAFETY DATA IN THE DIGITAL ERA. Journal of Healthcare and Life- Science ResearchVol. 3, No. 06, 2024 ISSN: 2181-4368.
9.Sylvia Lucas, Jessica Ailani, Timothy R. Smith, Ahmad Abdrabboh, Fei Xue and Marco S. Navetta. Pharmacovigilance: reporting requirements throughout a product's life cycle Ther At Drug Saf2022, Vol 13:1-16001161177/204709271125006.
10.Katharine Valéria Saraiva Hodel Bianca Sampaio Dotto Fiuza , Rodrigo Souza Conceição Augusto Cezar Magalhães Aleluia , Thassila Nogueira Pitanga, Larissa Moraes dos Santos Fonseca Camila Oliveira Valente Cintia Silva Minafra-Rezende and Bruna Aparecida Souza Machado Pharmacovigilance in Vaccines: Importance, Main Aspects ,Perspectives, and Challenges—A Narrative Review Pharmaceuticals 2024, 17, 807.https://doi.org/10.3390/ph17060807.
11.AMITHA SHETTY, AKHILESH DUBEY,ALAFIYA MATCHESWALA1 and SHILPABANGERA1Pharmacovigilance Systems and Strategies: Importance of Post-Marketing Surveillance for Ensuring Drug Safety and Patient Health in Europe, United States, and India. February 25, 2023.
12.Harshal S. Rele Akansha Pate1PHARMACOVIGILANCE PROGRAMME OF INDIA : AN OVERVIEW Pharmaceutical Resonance 2023 Vol. V - Issue II.
13.Nitesh Kumar, Mukesh Darshan Farzana Islam1Ensuring global health: a comprehensive review of vaccine regulation with a focus on the Indian perspective International Journal of Community Medicine and Public Health2024 Feb;11(2):989-993.
14.Nasrullah Abbasi, Nizamullah FNU, Shah Zeb AI IN HEALTHCARE: USING CUTTING-EDGE TECHNOLOGIES TO REVOLUTIONIZE VACCINE DEVELOPMENT AND DISTRIBUTIONJURIHUM: Jurnal Inovasi dan Humaniora Volume 1, No.1 Juni, 2023 ISSN 3025- 7409 (Media Online)Hal 17-29.
15.WHO. National regulatory authorities for vaccines, 2021. Available at: https://www.who.int/teams/ regulation prequalification/regulatory-authorities. Accessed on 23 May 2023.
16.Nitesh Kumar1,Mukesh Darshan2, Farzana Islam. Ensuring global health: a comprehensive review of vaccine regulation with a focus on the Indian perspective International Journal of Community Medicine and Public Health Kumar N. Int J Community Med Public Health. 2024 Feb;11(2):989-993http://www.ijcmph.com pISSN 2394-6032 | eISSN 2394-6040
17.Jaypee Brothers Medical Publishers (P) Ltd Editors: Vipin M. Vashishtha National Vaccine Policy of India January 2014 DOI:10.5005/jp/books/12311_59.